Reinier Haga Groep Orthopedisch Centrum B.V.

The medical center is at the forefront of research in prosthetic joint infection (PJI), focusing on innovative treatment strategies. The RiCOTTA trial is a pivotal study exploring the efficacy of targeted monotherapy with clindamycin during the oral treatment phase, compared to the traditional combination of rifampicin and fluoroquinolones.

• Prosthetic Joint Infection Management
• Antibiotic Monotherapy
• Combination Antibiotic Therapy

This research aims to redefine treatment protocols, potentially reducing the complexity and side effects associated with combination therapies, thereby enhancing patient outcomes in PJI management.

In the realm of venous thromboembolism (VTE), the DISTINCT trial is a landmark study that evaluates personalized thrombosis prophylaxis strategies for patients undergoing total hip or knee replacement. This trial investigates the effectiveness of tailored prophylaxis based on individual VTE risk levels, challenging the conventional 'one size fits all' approach.

• Personalized Thrombosis Prophylaxis
• Risk Stratification in VTE
• Postoperative VTE Prevention

The findings from this research are expected to influence clinical guidelines, promoting safer and more effective thrombosis prevention strategies tailored to patient-specific risk profiles.